Greenbrook TMS: investor resolution, TMS projection shortfall

Greenbrook TMS Inc., an operator of clinic networks providing transcranial magnetic stimulation therapy for treatment-resistant depression and other mental health conditions, settled a securities class action in which investors alleged that financial projections and positive statements about the company's operational trajectory were inconsistent with internal information about actual clinic-level economics — including insurance authorization challenges, treatment completion rates, and cash consumption that diverged from the picture being presented to the market during the class period.DOCUMENTED

Greenbrook built a network of TMS-focused treatment centers across multiple states, relying on insurance reimbursement for the therapy as its primary revenue source. The business model required achieving a specific combination of patient volume, completed treatment sessions, and reimbursement rates per session to generate revenue sufficient to cover fixed clinic operating costs and corporate overhead. When those variables underperform the projections embedded in public guidance, the divergence is visible internally through real-time operational data before it appears in quarterly financial results.

TMS Clinic Economics and the Reimbursement Variable

TMS therapy reimbursement varies across insurance payers in ways that significantly affect per-clinic economics. Coverage policies differ among commercial insurers on the number of sessions covered per course of treatment, prior authorization requirements, step-therapy prerequisites, and documentation requirements for authorization approval. When payer policies become less favorable — through added authorization steps, reduced covered session counts, or more restrictive documentation requirements — the impact on clinic revenue is felt immediately through authorization approval rates and completed-session data visible to management in real time.REVIEWED

The class action alleged that insurance authorization challenges were occurring during the class period at levels that made the financial projections embedded in public guidance unreachable, and that management had internal visibility into these challenges while simultaneously making statements about the company's operational trajectory that reflected more favorable assumptions. The gap between what management knew from internal clinic economics data and what was being communicated in investor-facing statements was the core of the securities fraud allegation.DOCUMENTED

Clinic-level data on authorization approval rates was available in real time. Public projections assumed approval rates and session completion levels that the actual data did not support during the class period.

Why Healthcare Service Operator Projections Carry Disclosure Risk

Growth-stage healthcare service operators face specific disclosure risks because the unit economics of new clinic rollouts are highly sensitive to variables that management tracks with granular precision but that external investors cannot independently observe. Authorization rates, treatment completion percentages, payer mix, and session reimbursement rates are internal operational metrics that directly drive revenue per clinic — and management has real-time visibility into all of them, while investors must rely on management's periodic communications for any insight into how those variables are performing against plan.REVIEWED

When these variables are underperforming the assumptions embedded in public financial projections, and management is aware of that underperformance from internal data, continued public projection of figures based on the favorable assumptions may constitute a material misrepresentation of the company's financial trajectory. The securities laws require disclosure of material adverse information on a timely basis — a standard that does not permit withholding unfavorable operational data while management attempts to improve performance before disclosing.REVIEWED

Settlement and Recovery

Greenbrook's subsequent financial restructuring constrained the recovery available to class members. In a bankruptcy-proximate context, settlement is typically funded from directors and officers liability insurance rather than operating assets, and coverage limits effectively cap class recovery regardless of the magnitude of investor harm alleged. The settlement structure reflected the company's financial condition at the time of resolution, producing a recovery that was bounded by available insurance coverage rather than by the scope of the alleged misrepresentation.

Companies in situations similar to Greenbrook's should implement disclosure processes that specifically address triggers for material adverse disclosure across each key performance variable underlying their financial projections — and should treat the gap between projected and actual performance on any key variable as a potential disclosure obligation rather than an operational challenge to be resolved before disclosure is considered. Getting that timing right — disclosing adverse operational developments when they become material rather than when they become unavoidable to report — is the core discipline that the securities fraud case law in this area requires, and it is a discipline that healthcare service growth companies with volatile unit economics and multi-variable performance dependencies need to build into their investor communications programs with particular rigor.

Companies in situations similar to Greenbrook's should implement disclosure processes that specifically address triggers for material adverse disclosure across each key performance variable underlying their financial projections — and should treat the gap between projected and actual performance on any key variable as a potential disclosure obligation rather than an operational challenge to be resolved before disclosure is considered. Getting that timing right — disclosing adverse operational developments when they become material rather than when they become unavoidable to report — is the core discipline that the securities fraud case law in this area requires, and it is a discipline that healthcare service growth companies with volatile unit economics and multi-variable performance dependencies need to build into their investor communications programs with particular rigor.

Companies in situations similar to Greenbrook's should implement disclosure processes that specifically address triggers for material adverse disclosure across each key performance variable underlying their financial projections — and should treat the gap between projected and actual performance on any key variable as a potential disclosure obligation rather than an operational challenge to be resolved before disclosure is considered. Getting that timing right — disclosing adverse operational developments when they become material rather than when they become unavoidable to report — is the core discipline that the securities fraud case law in this area requires, and it is a discipline that healthcare service growth companies with volatile unit economics and multi-variable performance dependencies need to build into their investor communications programs with particular rigor.

Have documents relevant to this story? Reach us through our tips channel.